We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Pacific Biosciences (PACB) in Q4 Earnings?
Read MoreHide Full Article
Pacific Biosciences of California Inc. (PACB - Free Report) is scheduled to report fourth-quarter 2017 results on Feb 1.
Last quarter, the company posted a positive earnings surprise of 5%. Pacific Biosciences has underperformed the Zacks Consensus Estimate in two of the preceding four quarters, the average negative surprise being 1.9%. Let’s see how things are shaping up prior to this announcement.
Key Factors
In the past quarters, product revenues demonstrated consistent uptrend on strength in consumable revenues. However, the Zacks Consensus Estimate for the fourth-quarter product revenue stands at $18.6 million, reflecting an expected year-over-year decline by 10.7%. We believe that the termination of the agreement with F. Hoffman-La Roche Ltd effective February 2017 is likely to affect revenues in the yet-to-be reported quarter. The agreement had been signed for the development and supply of diagnostic products based on Pacific Biosciences’ Single Molecule, Real-Time (SMRT) technology.
Pacific Biosciences of California, Inc. Price and EPS Surprise
Similar to the last two quarters, Pacific Biosciences’ fourth-quarter service and other revenues are expected to decline from the prior-year quarter. The decline was led by higher price RS service contracts being replaced with lower price sequel contracts. The Zacks Consensus Estimate for service revenues stands at $3.5 million for the fourth quarter, reflecting an expected year-over-year decline of 6.8%.
However, the company expects service revenue and service related costs to level out and improve, leading to improved gross margin in the yet-to-be reported quarter.
Here are the other factors that might influence Pacific Biosciences’ fourth-quarter results:
For 2017, the company expects 8-10% rise in operating expenses on a year-over-year basis. Further, management projects a loss for 2017 on a reported basis. Meanwhile, operating expenses in the third quarter of 2017 totaled $29.8 million, compared with $29.4 million a year ago. We expect the trend to affect the fourth-quarter bottom line too.
The company continues to see significant strength in China business. Sales in China last quarter was more than 30% of the total sales. With China being the fourth-largest developing nation (in terms of nominal GDP), we believe the progress in the country will open up channels for Pacific Biosciences, thereby driving its top line.
The Zacks Consensus Estimate for fourth-quarter revenues is $22 million, reflecting a 15.4% decline from the year-ago quarter. The Zacks Consensus Estimate for the bottom line is pegged at a loss of 19 cents, narrower than the year-ago loss of 21 cents.
Here is what our quantitative model predicts:
Pacific Biosciences does not have the right combination of two main ingredients — a positive Earnings ESP and Zacks Rank #3 (Hold) or higher — for increasing the odds of an earnings beat.
Zacks ESP: The Earnings ESP for Pacific Biosciences is +6.49%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Pacific Biosciences carries a Zacks Rank #4 (Sell).
Stocks to Consider
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
Myriad Genetics (MYGN - Free Report) has an Earnings ESP of +0.42% and a Zacks Rank #3.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.09% and a Zacks Rank #3.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
What's in Store for Pacific Biosciences (PACB) in Q4 Earnings?
Pacific Biosciences of California Inc. (PACB - Free Report) is scheduled to report fourth-quarter 2017 results on Feb 1.
Last quarter, the company posted a positive earnings surprise of 5%. Pacific Biosciences has underperformed the Zacks Consensus Estimate in two of the preceding four quarters, the average negative surprise being 1.9%. Let’s see how things are shaping up prior to this announcement.
Key Factors
In the past quarters, product revenues demonstrated consistent uptrend on strength in consumable revenues. However, the Zacks Consensus Estimate for the fourth-quarter product revenue stands at $18.6 million, reflecting an expected year-over-year decline by 10.7%. We believe that the termination of the agreement with F. Hoffman-La Roche Ltd effective February 2017 is likely to affect revenues in the yet-to-be reported quarter. The agreement had been signed for the development and supply of diagnostic products based on Pacific Biosciences’ Single Molecule, Real-Time (SMRT) technology.
Pacific Biosciences of California, Inc. Price and EPS Surprise
Pacific Biosciences of California, Inc. Price and EPS Surprise | Pacific Biosciences of California, Inc. Quote
Similar to the last two quarters, Pacific Biosciences’ fourth-quarter service and other revenues are expected to decline from the prior-year quarter. The decline was led by higher price RS service contracts being replaced with lower price sequel contracts. The Zacks Consensus Estimate for service revenues stands at $3.5 million for the fourth quarter, reflecting an expected year-over-year decline of 6.8%.
However, the company expects service revenue and service related costs to level out and improve, leading to improved gross margin in the yet-to-be reported quarter.
Here are the other factors that might influence Pacific Biosciences’ fourth-quarter results:
For 2017, the company expects 8-10% rise in operating expenses on a year-over-year basis. Further, management projects a loss for 2017 on a reported basis. Meanwhile, operating expenses in the third quarter of 2017 totaled $29.8 million, compared with $29.4 million a year ago. We expect the trend to affect the fourth-quarter bottom line too.
The company continues to see significant strength in China business. Sales in China last quarter was more than 30% of the total sales. With China being the fourth-largest developing nation (in terms of nominal GDP), we believe the progress in the country will open up channels for Pacific Biosciences, thereby driving its top line.
The Zacks Consensus Estimate for fourth-quarter revenues is $22 million, reflecting a 15.4% decline from the year-ago quarter. The Zacks Consensus Estimate for the bottom line is pegged at a loss of 19 cents, narrower than the year-ago loss of 21 cents.
Here is what our quantitative model predicts:
Pacific Biosciences does not have the right combination of two main ingredients — a positive Earnings ESP and Zacks Rank #3 (Hold) or higher — for increasing the odds of an earnings beat.
Zacks ESP: The Earnings ESP for Pacific Biosciences is +6.49%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Pacific Biosciences carries a Zacks Rank #4 (Sell).
Stocks to Consider
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
Bio-Rad Laboratories (BIO - Free Report) has an Earnings ESP of +4.45% and a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Myriad Genetics (MYGN - Free Report) has an Earnings ESP of +0.42% and a Zacks Rank #3.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.09% and a Zacks Rank #3.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>